The Gavel wrote:So the business plan of ACL is give us your...

The Gavel wrote:
So the business plan of ACL is give us your money and shut up and go away til we first develop a drug and then go through the regulatory process of approval at someone elses convenience and then we will have something to take to market.

That's the business plan of pretty much every biotech company. If you don't like the sector as a whole, that's perfectly understandable, but there's nothing in your rants at all specific to Alchemia.

In case you aren't aware, Alchemia's lead product is a fully synthetic generic. This means that a) there's much less uncertainty about the FDA approval (basically only purity and quality control issues, since it's chemically identical to an existing product) and b) there's much less uncertainty about the market size (since we know what current Arixtra sales are). We're effectively looking at risks in approval timing and in market share, not general uncertainties.

In my opinion, this makes Alchemia much less risky than most biotech companies without products in the market. Your concerns are valid, but they are much bigger concerns for Alchemia's peers, so in that sense they are actually pluses for Alchemia!